track pipelin updat drive materi chang
pharma estim remicad actelion zytiga
impli pharma growth key focu item
quarter pt move multipl contract
 get back track quarter debat multipl quarter
center pharmaceut acceler whether pipelin off-set
pressur remicad zytiga sentiment around debat turn
neg last quarter remicad price competit intensifi zytiga risk came
focu actelion slow impli pharmaceut guidanc
also slower result commentari around
point import determin whether multipl discount
versu narrow
februari track line us pharma estim modest chang
model analysi script drug price track suggest
us pharma growth estim line januari februari im
trend note im tracker suggest possibl upsid stelara
immunolog invega sustenna/trinza neurosci zytiga oncolog
estim enough us materi chang estim
drug time reduc us darzalex oncolog estim
given weaker im trend model organ
growth pharma revenu
comfort remicad estim defens strategi remicad
consist leverag broader pharma portfolio contract discuss
rebat make remicad cost competit cheaper biosimilar
interchang biosimilar us import given
remicad patient stabl brand product limit
visibl outcom septemb lawsuit
alleg anti-competit practic note manag commentari indic
competit valu price help stem biosimilar impact date
comfort y/i us declin estim declin
beyond acknowledg risk addit biosimilar entrant
potenti litig uncertainti estim alreadi reflect signific
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
conservat see scenario manag abl limit sale
eros y/i vs estim declin bull case scenario
remicad eros control y/i declin see
pharma compound-annual-growth-rate benefit bp current estim
recap signific pharma newsflow quarter zytiga ipr erleada
approv signific newsflow updat quarter neg
zytiga ipr rule januari appeal see januari note
model gener launch expir month stay
octob year remind expect gener competitor
zytiga believ guidanc rang oper growth suffici
absorb neg zytiga court proceed futur prostat
cancer franchis increasingli depend upon erleada apalutamid
receiv fda approv non-metastat castration-resist prostat
cancer februari follow spartan phase trial show
decreas risk distant metastasi death improv median
mestasis-fre surviv year model previous assum
launch includ modest revenu contribut erleada
pipelin key pharma acceler year model organ
growth pharma await newsflow becom construct
back pharma acceler organ growth reach highest
organ growth level year organ guidanc left mani
investor underwhelm pharma growth main driver stock
perform view key driver lower growth outlook includ
remicad biosimilar impact softer actelion result outlook model
organ growth pharma upsid come pipelin key
upcom catalyst like includ erleada apalutamid uptak
approv earlier model uptak tremfya guselkumab
xarelto cad/pad indic expans darzalex approv frontlin
multipl myeloma nontranspl invokana mace indic expans
canvas/canvas-r-cv esketamin file potenti approv
catalyst key pharma acceler year
maintain equal-weight price target current trade
discount versu histor discount given
pharma growth like slightli better major pharma peer
guidanc may conserv see note detail potenti
acceler consum devic discount may sever
 broader organ growth profil improv year toward
seen move price target reflect
ep continu reflect discount
 biosimilar balanc pipelin balanc sheet margin expans
 biosimilar balanc pipelin balanc sheet margin expans
price target base multipl
base case ep assum trade slight discount
 given growth acceler pharma flexibl balanc
bull case ep
bull case ep
pharma pipelin exce expect due indic expans exist
franchis actelion surpass accret return target reinvest
pharma profit consum devic busi new commit return
addit sharehold buyback drive add ep
base ep
base ep
revenu growth acceler remicad sale eros off-set
pipelin contribut improv devic consum actelion
acquisit integr time near term accret limit initi
 invest trade slight discount line
bear ep
bear ep
revenu growth languish low singl digit amid deterior end
market remicad eros suffer aggress biosimilar price discount
addit entrant us market actelion integr fall track
md price pressur acceler multipl fall due structur
weaker revenu growth ineffici capit use long-term value-cr
pharma growth pipelin catalyst
off-set competit risk biosimilar
profil balanc improv segment
growth margin md consum
along margin expans initi
manag remain confid longer
term actelion accret growth
see potenti portfolio manag
expect divestitur ancillari slower
growth asset
pharma pipelin like take time
contribut near term risk
remicad biosimilar eros expect
margin initi remain track
model bp margin expans
manag also commit
reinvest upsid incom back
busi support growth
complet announc restructur
initi asset dispos
balanc sheet deploy
wacc return share repurchas
risk achiev price
anticip indic expans
exist pharma portfolio unabl off-set
investor worri around biosimilar
lower expect underli margin
expans benign price improv mix
wors expect fx headwind
greater expect price share
eros biosimilar across
exhibit sale ep
year year sale growth quarter date
quarter quarter sale growth quarter date
note us jv partnership cover ms
analyst david rising result pharmacycl acquisit book
us sale revenu profit share agreement place book net revenu
us imbruvica sale net residu profit earn sg reimburs
estim us imbruvica net revenu ou sale
imbruvica growth see increment benefit continu indic expans
effort includ recent fda approv relapsed/refractori margin zone
lymphoma said note acalabrutinib second-gener btk inhibitor
show better orr safeti cll patient ph studi may pose
longer term challeng compound current ph trial go
head head vs imbruvica core market high risk chronic lymphocyt leukemia
invokana daili type diabet treatment invokana first
inhibitor market follow astrazeneca farxiga recent boehringer/
lilli jardianc astrazeneca azn cover eu pharma team
cover ms analyst david rising note analysi group invokana
invokamet canagliflozin metformin farxiga xigduo dapagliflozin
market share perspect invokana continu see share loss
recent weekli data suggest share start
jardianc continu make inroad incumb
recent weekli read peg market share believ script track
indic jardianc cv benefit contribut share gain see cv
benefit class benefit benefit jardianc stand gain
rest plethora inhibitor market may also increas
potenti payer demand favor price use formulari
exclus pose anoth longer term threat note submit
snda invokana om octob seek new indic reduc risk
major advers cardiovascular event mace base find
canvas/canvs-r-cv outcom approv expect year
estim us invokana sale ou sale
stelara continu add pharma franchis immunolog model us
stelara revenu expect us growth fall growth
stelara saw us see signific benefit gross-to-net
adjust recent im data trend encourag continu
stelara face competit core psoriasi indic newer drug includ
novarti nv cosentyx inhibitor well valeant brodalumab anoth il-
molecul suffer safeti concern relat suicid ideat
also acknowledg recent ii result boehring ingelheim
compound similar safeti profil better efficaci stelara
note ms pharma analyst david rising announc global
collabor bi mab plaqu psoriasi compound
ixekizumab call taltz report higher respons rate vs stelara patient
moder sever plaqu psoriasi said note dermatologist tend
conserv stelara long safeti track record remain competit advantag
addit see effort indic expans stelara extend life-cycle
drug
xarelto continu leader anti-coagul market see eliqui
continu make gain said indic expans cad/pad
compass like contribut xarelto gain current model
us xarelto sale
im data week roll basi suggest xarelto held share sinc
last august note compass data set show signific prevent
major advers cardiac event patient coronari arteri diseas peripher
arteri diseas eliqui continu gain ground move xarelto share
script versu begin last quarter
normal around share major zytiga share
increas last year current year date versu xtandi level
last seen mid bit surpris share shift perceiv xtandi
advantag term requir co-prescript steroid vs
zytiga zytiga gener manufactur current face month stay end
nce exclus limit entri late octob expect earlier
gener launch follow neg ipr rule see januari note detail
thought continu model gener competit current model
us ou revenu
